Stefano Luminari
YOU?
Author Swipe
View article: Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials Open
View article: Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective Open
Follicular lymphoma (FL) is an indolent disease characterized by multiple relapses and eventual refractoriness to therapy. Despite advancements in therapeutic approaches, FL treatment algorithm and management remain not well‐established, n…
View article: Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL
Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL Open
Odronextamab, a CD20×CD3 bispecific antibody, demonstrated robust efficacy and durable responses, with a generally manageable safety profile, in patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (…
View article: A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection Open
Over the past 2 decades, advancements in follicular lymphoma (FL) treatment, particularly with anti‐CD20 antibodies, have significantly improved patient survival. However, a subset of FL patients experiences early relapse and progression w…
View article: Towards a chemo‐free approach for follicular lymphoma
Towards a chemo‐free approach for follicular lymphoma Open
Summary The therapeutic landscape of follicular lymphoma (FL) is undergoing a transformative shift driven by the advent of novel chemo‐free strategies that challenge the traditional chemo‐oriented paradigms; this shift offers promising alt…
View article: Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus Open
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of aggressive B-cell non-Hodgkin lymphoma, particularly in relapsed/refractory large B-cell lymphoma and mantle cell lymphoma. Despite its transformative poten…
View article: Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG) Open
The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective su…
View article: 254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY
254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY Open
View article: 234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
234 | POST HOC ANALYSIS OF OUTCOMES BY POD24 STATUS FROM THE inMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA Open
View article: 28 | OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
28 | OUTCOMES FROM THE PHASE 3 inMIND STUDY OF TAFASITAMAB (TAFA) PLUS LENALIDOMIDE (LEN) AND RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) Open
View article: 424 | LONGITUDINAL TARGETED ctDNA ANALYSIS TO ASSESS CD20 and BAFF MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY FL OR DLBCL PROGRESSING ON ODRONEXTAMAB IN THE ELM‐2 STUDY
424 | LONGITUDINAL TARGETED ctDNA ANALYSIS TO ASSESS CD20 and BAFF MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY FL OR DLBCL PROGRESSING ON ODRONEXTAMAB IN THE ELM‐2 STUDY Open
View article: 62 | A PHASE II TRIAL OF PEMBROLIZUMAB CONCURRENT WITH RADIOTHERAPY FOR FRAIL PATIENTS WITH NEWLY DIAGNOSED EARLY‐STAGE NATURAL KILLER/T‐CELL LYMPHOMA (IELSG50)
62 | A PHASE II TRIAL OF PEMBROLIZUMAB CONCURRENT WITH RADIOTHERAPY FOR FRAIL PATIENTS WITH NEWLY DIAGNOSED EARLY‐STAGE NATURAL KILLER/T‐CELL LYMPHOMA (IELSG50) Open
View article: 388 | CLINICAL OUTCOMES AND PROGNOSTIC FACTORS IN NODAL AGGRESSIVE T‐CELL LYMPHOMAS: INSIGHTS FROM 655 CASES REGISTERED IN THE T‐CELL PROJECT 2.0
388 | CLINICAL OUTCOMES AND PROGNOSTIC FACTORS IN NODAL AGGRESSIVE T‐CELL LYMPHOMAS: INSIGHTS FROM 655 CASES REGISTERED IN THE T‐CELL PROJECT 2.0 Open
View article: 259 | IELSG49: A PHASE II TRIAL OF ACALABRUTINIB IN COMBINATION WITH TAFASITAMAB IN PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMAS
259 | IELSG49: A PHASE II TRIAL OF ACALABRUTINIB IN COMBINATION WITH TAFASITAMAB IN PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMAS Open
View article: 387 | SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA; DATA FROM 110 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT 2
387 | SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA; DATA FROM 110 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT 2 Open
View article: 856 | MARSUN, A PHASE III, MULTICENTER, OPEN LABEL, RANDOMIZED STUDY INVESTIGATING MOSUNETUZUMAB‐LENALIDOMIDE VERSUS INVESTIGATOR CHOICES IN R/R MARGINAL ZONE LYMPHOMAS
856 | MARSUN, A PHASE III, MULTICENTER, OPEN LABEL, RANDOMIZED STUDY INVESTIGATING MOSUNETUZUMAB‐LENALIDOMIDE VERSUS INVESTIGATOR CHOICES IN R/R MARGINAL ZONE LYMPHOMAS Open
View article: 242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY
242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY Open
View article: 386 | NUMBER OF EXTRANODAL SITES IN PTCL AS PROGNOSTIC MARKER IN REAL‐WORLD SETTING. AN ANALYSIS OF 645 CASES ENROLLED IN THE T‐CELL PROJECT 2
386 | NUMBER OF EXTRANODAL SITES IN PTCL AS PROGNOSTIC MARKER IN REAL‐WORLD SETTING. AN ANALYSIS OF 645 CASES ENROLLED IN THE T‐CELL PROJECT 2 Open
View article: 52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
52 | RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED EXTRANODAL MARGINAL ZONE LYMPHOMAS: FIRST ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY Open
View article: 583 | COMPARATIVE EFFECTIVENESS OF ODRONEXTAMAB VERSUS REAL‐WORLD SYSTEMIC THERAPIES USED IN AN EXTERNAL CONTROL ARM IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
583 | COMPARATIVE EFFECTIVENESS OF ODRONEXTAMAB VERSUS REAL‐WORLD SYSTEMIC THERAPIES USED IN AN EXTERNAL CONTROL ARM IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA Open
View article: 223 | PROGNOSTIC ROLE OF INTERIM ΔSUVmax IN FOLLICULAR LYMPHOMA
223 | PROGNOSTIC ROLE OF INTERIM ΔSUVmax IN FOLLICULAR LYMPHOMA Open
View article: 14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0
14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0 Open
View article: 51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY
51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY Open
View article: 582 | EPCORITAMAB PLUS BENDAMUSTINE + RITUXIMAB FOR FIRST‐LINE TREATMENT OF FOLLICULAR LYMPHOMA: CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE NHL‐2 ARM 3
582 | EPCORITAMAB PLUS BENDAMUSTINE + RITUXIMAB FOR FIRST‐LINE TREATMENT OF FOLLICULAR LYMPHOMA: CLINICAL AND TRANSLATIONAL RESULTS FROM EPCORE NHL‐2 ARM 3 Open
View article: 277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI
277 | PREPHASE TREATMENT WITH VITAMIN D SUPPLEMENTATION IN OLDER PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: A RANDOMIZED TRIAL BY FONDAZIONE ITALIANA LINFOMI Open
View article: Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the <scp>FOLL12</scp> Trial
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub‐Study of the <span>FOLL12</span> Trial Open
Discordant results have been generated regarding the prognostic role of Total Metabolic Tumor Volume (TMTV) in Follicular Lymphoma (FL). The use of prospective data and the adoption of the newly defined standardized SUV4 method for calcula…
View article: Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi Open
We analyzed metabolic response using interim positron emission tomography scan (iPET) in a subset of patients with follicular lymphoma (FL) enrolled in the randomized FOLL12 trial. Patients with grade 1-3a FL with an iPET performed between…
View article: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial Open
The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse la…
View article: Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study Open
View article: Identifying unmet needs in cancer survivorship by linking patient-reported outcome measures to the International Classification of Functioning, Disability and Health
Identifying unmet needs in cancer survivorship by linking patient-reported outcome measures to the International Classification of Functioning, Disability and Health Open